Several analysts have recently updated their ratings and price targets for Shield Therapeutics PLC (LON: STX):

  • 10/10/2017 – Shield Therapeutics PLC had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 245 ($3.22) price target on the stock.
  • 9/22/2017 – Shield Therapeutics PLC had its price target lowered by analysts at FinnCap from GBX 270 ($3.55) to GBX 265 ($3.48). They now have a “buy” rating on the stock.
  • 9/20/2017 – Shield Therapeutics PLC had its “buy” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 220 ($2.89) price target on the stock.
  • 9/20/2017 – Shield Therapeutics PLC had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 245 ($3.22) price target on the stock.
  • 9/14/2017 – Shield Therapeutics PLC had its “buy” rating reaffirmed by analysts at FinnCap. They now have a GBX 270 ($3.55) price target on the stock.
  • 9/14/2017 – Shield Therapeutics PLC had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 245 ($3.22) price target on the stock.
  • 9/7/2017 – Shield Therapeutics PLC is now covered by analysts at FinnCap. They set a “buy” rating and a GBX 270 ($3.55) price target on the stock.
  • 9/6/2017 – Shield Therapeutics PLC had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 245 ($3.22) price target on the stock.

Shield Therapeutics PLC (LON:STX) opened at 155.00 on Wednesday. The firm’s market cap is GBX 180.46 million. Shield Therapeutics PLC has a 1-year low of GBX 155.00 and a 1-year high of GBX 175.00. The firm has a 50-day moving average price of GBX 157.50 and a 200-day moving average price of GBX 161.69.

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.

Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.